CA2947963A1 - Peptide vaccine comprising mutant ras peptide and chemotherapeutic agent - Google Patents

Peptide vaccine comprising mutant ras peptide and chemotherapeutic agent Download PDF

Info

Publication number
CA2947963A1
CA2947963A1 CA2947963A CA2947963A CA2947963A1 CA 2947963 A1 CA2947963 A1 CA 2947963A1 CA 2947963 A CA2947963 A CA 2947963A CA 2947963 A CA2947963 A CA 2947963A CA 2947963 A1 CA2947963 A1 CA 2947963A1
Authority
CA
Canada
Prior art keywords
peptide
mutation
seq
chemotherapeutic agent
cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA2947963A
Other languages
English (en)
French (fr)
Inventor
Jon Amund Eriksen
Gustav Gaudernack
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Circio Holding ASA
Original Assignee
Targovax ASA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=50679896&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CA2947963(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Targovax ASA filed Critical Targovax ASA
Publication of CA2947963A1 publication Critical patent/CA2947963A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001154—Enzymes
    • A61K39/001164—GTPases, e.g. Ras or Rho
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/82—Translation products from oncogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5158—Antigen-pulsed cells, e.g. T-cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55522—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
    • A61K2039/585—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation wherein the target is cancer

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Oncology (AREA)
  • Cell Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Virology (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Biotechnology (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
CA2947963A 2014-05-06 2015-05-05 Peptide vaccine comprising mutant ras peptide and chemotherapeutic agent Abandoned CA2947963A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP14167265 2014-05-06
EP14167265.9 2014-05-06
PCT/EP2015/059861 WO2015169804A1 (en) 2014-05-06 2015-05-05 Peptide vaccine comprising mutant ras peptide and chemotherapeutic agent

Publications (1)

Publication Number Publication Date
CA2947963A1 true CA2947963A1 (en) 2015-11-12

Family

ID=50679896

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2947963A Abandoned CA2947963A1 (en) 2014-05-06 2015-05-05 Peptide vaccine comprising mutant ras peptide and chemotherapeutic agent

Country Status (16)

Country Link
US (1) US9757439B2 (enExample)
EP (1) EP3140320B1 (enExample)
JP (2) JP2017514847A (enExample)
KR (1) KR20170002563A (enExample)
CN (1) CN106414493A (enExample)
AU (1) AU2015257774B2 (enExample)
BR (1) BR112016025764A2 (enExample)
CA (1) CA2947963A1 (enExample)
CL (1) CL2016002794A1 (enExample)
DK (1) DK3140320T3 (enExample)
ES (1) ES2716923T3 (enExample)
IL (1) IL248671B (enExample)
MX (1) MX2016014414A (enExample)
RU (1) RU2700929C2 (enExample)
SG (2) SG10201809701TA (enExample)
WO (1) WO2015169804A1 (enExample)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT3079715T (pt) 2013-12-09 2018-08-02 Targovax Asa Uma mistura de péptidos
EP3532070A1 (en) 2016-10-26 2019-09-04 Modernatx, Inc. Messenger ribonucleic acids for enhancing immune responses and methods of use thereof
EP3576780A1 (en) * 2017-02-01 2019-12-11 Modernatx, Inc. Immunomodulatory therapeutic mrna compositions encoding activating oncogene mutation peptides
EP3576764A4 (en) * 2017-02-03 2020-12-16 The Medical College of Wisconsin, Inc. KRAS PEPTIDIC VACCINE COMPOSITIONS AND METHOD OF USE
WO2019246286A1 (en) 2018-06-19 2019-12-26 Neon Therapeutics, Inc. Neoantigens and uses thereof
WO2020002650A1 (en) 2018-06-29 2020-01-02 Targovax Asa A formulation
CN109550044B (zh) * 2018-10-19 2022-05-03 杭州纽安津生物科技有限公司 通用性多肽疫苗及其在制备治疗/预防胰腺癌药物中的应用
WO2020252039A1 (en) * 2019-06-12 2020-12-17 Biontech Us Inc. Neoantigen compositions and uses thereof
CN113416241B (zh) * 2020-04-09 2022-04-08 北京臻知医学科技有限责任公司 一种用于诱导肿瘤特异性免疫响应的通用型抗原肽库及试剂盒
WO2022026620A1 (en) * 2020-07-29 2022-02-03 Sqz Biotechnologies Company Methods to stimulate immune responses to mutant ras using nucleated cells
EP4188425B1 (en) * 2020-07-29 2025-05-14 Stemcell Technologies Canada Inc. Methods to stimulate immune responses to mutant ras using anucleate cells
AU2021389909A1 (en) * 2020-11-24 2023-06-22 Shanghai GenBase Biotechnology Co., Ltd. Ras mutant epitope peptide and t cell receptor recognizing ras mutant
JP2024541968A (ja) * 2021-10-28 2024-11-13 ジェネンテック， インコーポレイテッド 治療的介入のためにｍｈｃ関連抗原を同定するためのシステムおよび方法
WO2023220434A2 (en) * 2022-05-12 2023-11-16 The Johns Hopkins University Neoantigen vaccines for cancer prevention
WO2025103205A1 (en) * 2023-11-15 2025-05-22 Ck Life Sciences Development Limited Pharmaceutical compositions and methods for preventing or treating kras-associated diseases or conditions

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9103974D0 (en) * 1991-02-26 1991-04-10 Norsk Hydro As Therapeutically useful peptides or peptide fragments
GB2328689A (en) 1997-08-27 1999-03-03 Norsk Hydro As Peptides based on the p21 ras proto-oncogene protein for the treatment of cancer
NO309798B1 (no) * 1999-04-30 2001-04-02 Targovax As Peptidblanding, samt farmasoytisk sammensetning og kreftvaksine som innbefatter peptidblandingen
KR101241272B1 (ko) 2002-12-16 2013-03-15 더 리젠츠 오브 더 유니버시티 오브 콜로라도, 어 바디 코포레이트 면역 요법으로서의 효모계 백신
US20140199405A1 (en) * 2013-01-11 2014-07-17 Abraxis Bioscience, Llc Method for treating cancer based on mutation status of k-ras
PT3079715T (pt) 2013-12-09 2018-08-02 Targovax Asa Uma mistura de péptidos

Also Published As

Publication number Publication date
AU2015257774B2 (en) 2018-12-20
SG11201608712PA (en) 2016-11-29
JP7304629B2 (ja) 2023-07-07
RU2016147527A (ru) 2018-06-08
RU2700929C2 (ru) 2019-09-24
ES2716923T3 (es) 2019-06-18
KR20170002563A (ko) 2017-01-06
CL2016002794A1 (es) 2017-06-09
EP3140320B1 (en) 2018-12-26
DK3140320T3 (en) 2019-04-15
US20170065694A1 (en) 2017-03-09
BR112016025764A2 (pt) 2018-01-16
US9757439B2 (en) 2017-09-12
IL248671B (en) 2021-08-31
AU2015257774A1 (en) 2016-12-22
RU2016147527A3 (enExample) 2019-01-21
SG10201809701TA (en) 2018-12-28
JP2020100650A (ja) 2020-07-02
MX2016014414A (es) 2017-02-23
EP3140320A1 (en) 2017-03-15
WO2015169804A1 (en) 2015-11-12
JP2017514847A (ja) 2017-06-08
IL248671A0 (en) 2017-01-31
CN106414493A (zh) 2017-02-15

Similar Documents

Publication Publication Date Title
EP3140320B1 (en) Peptide vaccine comprising mutant ras peptide and chemotherapeutic agent
EP2113253B1 (en) Novel formulations of tumour-associated peptides binding to human leukocyte antigen (HLA) class I or II molecules for vaccines
JP6042211B2 (ja) ポリペプチド
JP2025084910A (ja) タンパク質抗原およびその使用
KR20180129899A (ko) 신생항원 및 이것의 사용 방법
US9539299B2 (en) Combination therapy with WT1 peptide vaccine and temozolomide
AU2020337869A1 (en) IL-15 conjugates and uses thereof
Katakami et al. Phase I/II study of tecemotide as immunotherapy in Japanese patients with unresectable stage III non-small cell lung cancer
CN117813108A (zh) 基于肽的新抗原疫苗的多组分化学组合物
KR20220143812A (ko) B형 간염 바이러스와 관련된 질병의 치료
RU2709015C2 (ru) Лекарственное средство
CN118251406A (zh) 血管活性肠肽(vip)受体拮抗剂
AU2017440798C1 (en) Improved treatment of cancer
HK1231899B (en) Peptide vaccine comprising mutant ras peptide and chemotherapeutic agent
HK1231899A1 (en) Peptide vaccine comprising mutant ras peptide and chemotherapeutic agent
Jin et al. Application of dsRNA in cancer immunotherapy: Current status and future trends
AU2016289727B2 (en) Immunogenic preprocalcitonin peptides
EP3773690A1 (en) New vaccinal strategy
RU2773273C2 (ru) Неоантигены и способы их использования
WO2018088933A1 (en) Anti-tumor effects of a viral vector encoding a toll-like receptor and a toll-like receptor agonist
HK40004257A (en) Neoantigens and methods of their use

Legal Events

Date Code Title Description
FZDE Discontinued

Effective date: 20211123